United Therapeutics extends credit facility maturity to March 31, 2028

UNITED THERAPEUTICS Corp

Extended maturity of $1.2B and $800M unsecured revolving credit facilities by one year to March 31, 2028.
Extension effective March 31, 2023, per Section 2.7 of the Credit Agreement originally dated March 31, 2022.
Facilities may be increased by up to $500M aggregate subject to commitments and conditions.
No other changes to terms; borrowing capacity remains unchanged.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

UNITED THERAPEUTICS Corp amended Credit Agreement with Wells Fargo Bank, National Association, as administrative agent (effective 2023-03-31).

Action: amendment
Agreement: credit facility
Counterparty: Wells Fargo Bank, National Association, as administrative agent
Effective: 2023-03-31

Exact text from the filing

Pursuant to Section 2.7 of the Credit Agreement, the maturity of the commitments and loans of each lender under the Credit Agreement has been extended by one year to March 31, 2028. The maturity extension became effective as of March 31, 2023.

View on SEC.gov

Browse all material agreements →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-040233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.